Mpox Clade Ib Cases Rise in Europe, Sparking Vaccination Recommendations
Table of Contents
Recent reports indicate a rise in mpox (formerly known as monkeypox) cases across Europe, specifically involving the Clade Ib strain. While the UK has seen cases linked to travel, several EU/EEA countries are now reporting locally acquired infections, suggesting a shift in transmission patterns and prompting renewed vaccination recommendations, particularly ahead of Winter Pride season.
Current Situation: UK and Europe
As of late October 2024, the UK has identified 16 cases of mpox Clade Ib, all located in England. Importantly, these cases have been directly or indirectly linked to recent travel to countries where the strain is currently circulating. https://www.gov.uk/government/news/ukhsa-statement-on-mpox-cases
Though, a different picture is emerging in other parts of Europe. Spain reported its first locally-acquired cases earlier this month, and Italy, Portugal, and the Netherlands have collectively reported four additional cases among men. These five cases presented with mild symptoms.
The European center for Disease Prevention and Control (ECDC) notes that these recent cases have no reported travel history. this suggests “a different pattern of transmission” and indicates that the virus may be spreading through sexual networks among men who have sex with men (MSM) in several EU/EEA countries.https://www.ecdc.europa.eu/en/news-events/mpox-clade-ib-cases-reported-europe
Previously reported Clade I mpox cases in Europe – around 30 – were all either imported or clearly linked to imported cases. This new development signals a potential resurgence of community transmission.
Vaccination Recommendations
Given the evolving situation, health officials are urging caution and recommending vaccination, especially for those at higher risk. Richard Angell OBE, chief executive of the Terrence Higgins Trust, emphasized the importance of vaccination for individuals traveling to Winter Pride events across Europe. https://www.tht.org.uk/news/mpox-clade-ib-cases-rise-europe-prompting-vaccination-advice
Most individuals are eligible for a two-dose vaccination schedule, with doses administered at least 28 days apart. Vaccination remains the most effective way to protect against mpox and prevent severe illness.
Understanding Mpox and Clades
Mpox is a viral infection that can cause a rash, fever, headache, muscle aches, and swollen lymph nodes. It spreads through close contact with an infected person or animal, or with materials contaminated with the virus.
There are two main clades of the mpox virus: Clade I and Clade II. The current global outbreak is primarily associated with Clade IIb. Though, the recent cases in Europe involve Clade Ib, a different genetic branch of the virus. Understanding these different clades is notable for tracking the spread of the virus and assessing the effectiveness of control measures.
Key Takeaways:
* Rising Cases: mpox Clade Ib cases are increasing in Europe,with a shift towards local transmission.
* Travel Link disrupted: Recent cases in several EU/EEA countries have no known travel history,suggesting community spread.
* MSM at Risk: The ECDC suggests transmission may be occurring within sexual networks among men who have sex with men.
* Vaccination is Key: Vaccination is strongly recommended, particularly for those traveling to events like Winter Pride.
* Two-Dose Schedule: The recommended vaccination schedule involves two doses, at least 28 days apart.
Looking Ahead
Continued surveillance and genomic sequencing are crucial to monitor the spread of mpox Clade Ib and understand its transmission dynamics. Public health authorities will continue to provide updates and guidance as the situation evolves. Individuals should stay informed about the latest recommendations and take appropriate precautions to protect themselves and others.
Related reading